Recent Updates
Recently added Catalysts
JSPR Negative Sentiment Score: 20/100

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR

Key Takeaway: Jasper Therapeutics, Inc. is facing a class action lawsuit filed by investors for alleged violations of securities laws. The lawsuit claims that the company made false and misleading statements regarding its manufacturing partners and the impact on clinical trials. The class period for the lawsuit covers November 30, 2023, to July 3, 2025, with a deadline for shareholder participation set for November 18, 2025. Investors are encouraged to contact the DJS Law Group for potential recovery options.

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit indicates serious legal issues for Jasper Therapeutics.
  • Allegations of false and misleading statements may lead to financial consequences.
  • Insufficient control over third-party manufacturing raised risks for the company.
  • Clinical trials at risk due to problems with manufacturing partners.

Full Press Release Details

LOS ANGELES, Oct. 27, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Shareholders who purchased shares of JSPR during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: November 30, 2023 to July 3, 2025
DEADLINE: November 18, 2025
CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Jasper’s controls over third-party manufacturing was insufficient to ensure its vendors followed all applicable rules and regulations. The Company’s clinical trials were placed at risk due to problems with its manufacturing partners. Based on these facts, Jasper’s public statements were false and materially misleading throughout the class period.
If you are a shareholder who suffered a loss, contact us to participate.
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case.
WHY DJS LAW GROUP? DJS Law Group’s primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results.
Join the case to recover your losses.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
274 White Plains Road, Suite 1
Eastchester, NY 10709

Tags

Frequently Asked Questions

What is the class action against Jasper Therapeutics about?

The lawsuit alleges Jasper Therapeutics made false statements about its manufacturing processes.

What is the class period for the Jasper lawsuit?

The class period is from November 30, 2023, to July 3, 2025.

What is the deadline to join the class action?

The deadline to join the class action is November 18, 2025.

Do I need to be a lead plaintiff to recover losses?

No, lead plaintiff appointment is not necessary to participate in the recovery.

What can shareholders expect after registering?

Registered shareholders will receive updates through a portfolio monitoring system.

Last updated: Oct 27, 2025